Inhalerx Share Price and Company Fundamentals
Last traded: Today at 12:40 AM
InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
-
Beta
-0.29
Market cap
$5.42M
Enterprise value
$4.55M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://inhalerx.com.au |
| Mailing address | 505 Little Collins Street Level 9 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 8678 4091 / 61 3 8678 1747 |
Dividends
More: Inhalerx Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Inhalerx paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.IRX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Inhalerx.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Darryl Davies B.Sc. | Chief Executive Officer | ||
| Dr. Robert Jenny B.A., B.Sc., Ph.D. | Chief Scientific Officer | ||
| Greg Hammond | Chief Financial Officer | ||
| Mr. Srinivasa Rao Suryadevara | Executive Vice President | 56 |
Profitability and management effectiveness
Profit margin
-159.03%
Operating margin
-143.46%
Return on assets
-86.50%
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Inhalerx is 5.42M and its enterprise value is 4.55M. The enterprise value to revenue ratio of IRX is 5.46. The enterprise value to EBITDA ratio of IRX is -.
Companies similar to Inhalerx (IRX)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Pro Medicus (PME)
- Polynovo (PNV)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Inhalerx (ASX:IRX) Frequently Asked Questions
1. What is Inhalerx's Stock Symbol?
Inhalerx trades on ASX under the ticker symbol "IRX".
2. What is Inhalerx's stock price today?
One share of IRX stock can currently be purchased for approximately $0.022.
3. How can I contact Inhalerx?
Inhalerx's mailing address is 505 Little Collins Street Level 9 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 8678 4091.
4. What is Inhalerx's official website?
The official website of Inhalerx is https://inhalerx.com.au.